Statin-associated incident diabetes: A literature review

Consultant Pharmacist

Volumn 29, Issue 5, 2014, Pages 317-334

  Park, Zoon H ^a   Juska, Alicia ^a   Dyakov, Detelin ^a   Patel, Ramesh V ^a  

^a SWEDISH COVENANT HOSPITAL   (United States)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Elderly; HMG CoA reductase inhibitors; Incident

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

DIABETES MELLITUS; HUMAN; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; META ANALYSIS (TOPIC); REVIEW; RISK FACTOR; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; META ANALYSIS;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84908650251     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2014.317     Document Type: Review

References (69)

1. Grabowski DC, Lakdawalla DN, Goldman DP et al. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff (Millwood) 2012;31:2276-85.
2. Cohen JD, Brinton EA, Ito MK et al. Understanding statin use in America and gaps in patient education (USAGE): an Internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012;6:208-15.
3. Gotto Jr AM. Over-the-counter statins are worth considering in primary prevention of cardiovascular disease. Circulation 2006;114: 1310-4.
4. Ridker PM, Danielson E, Fonseca FA et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
5. Jick SS, Bradbury BD. Statin and newly diagnosed diabetes. Br J Clin Pharmacol 2004;58:303-9.
6. Ma T, Tien L, Fang CL et al. Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther 2012:34:1977-83.
7. Culver AL, Ockene IS, Balasubramanian R et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172:144-52.
8. Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol 2013;75: 1118-24.
9. Wang KL, Liu CJ, Chao TF et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012;60:1231-8.
10. Danaei G, Cantero OF, Rodriguez LAG et al. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 2013;36:1236-40.
11. Izzo R, de Simone G, Trimarco V et al. Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk. Nutr Metab Cardiovasc Dis 2013;23:1101-6.
12. Ko DT, Wijeysundera HC, Jackevicius CA et al. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins. Circ Cardiovasc Qual Outcomes 2013;6:315-22.
13. Carter AA, Gomes T, Camacho X et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013;346:f2610.
14. Coleman CI, Reinhart K, Kluger J et al. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opta 2008;24:1359-62.
15. Rajpathak SN, Barzilai N, Kumbhani DJ et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924-9.
16. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
17. Mills EJ, Wu P, Chong G et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170255 patients from 76 randomized trials. Q J Med 2011:104:109-24.
18. Preiss D, Seshasai SRK, Welsh P et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a metaanalysis. JAMA 2011;305:2556-64.
19. Alberton M, Wu P, Druyts E et al. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. Q J Med 2012;105:145-57.
20. Navarese EP, Buffon A, Andreotti F et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013;111:1123-30.
21. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246955 participants from 135 randomized controlled trials. Circ Cardiovasc Qual Outcomes 2013;6:390-9.
22. Palaniswamy C, Selvaraj DR, Selvaraj T et al. Mechanisms underlying pleiotropic effects of statins. Am J Ther 2010;17:75-8.
23. Bu DX, Griffin G, Lichtman AH. Mechanism for the antiinflammatory effects of statins. CurrOpin Lipidol 2011;22:165-70.
24. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-119.
25. Xia F, Xie L, Mihic A et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology 2008; 149:5136-45.
26. Golomb BA, Evans MA, Dimsdale JE et al. Effect of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012;172:1180-2.
27. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009;29:800-11.
28. Parker BA, Polk DM, Rabdiya V et al. Changes in memory function and neuronal activation associated with atorvastatin therapy. Pharmacotherapy 2010;30:625.
29. Machan CM, Hrynchak PK, Irving EL. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci 2012;89:1165-71.
30. Chong PH, Boskovich A, Stevkovic N et al. Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy 2004;24:1194-203.
31. Nakata M, Nagasaka S, Kusaka I et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006;49:1881-92.
32. Goldstein MR, Mascitelli L. Statin-induced diabetes: perhaps, it's the tip of the iceberg. Q J Med 2011;104:174-8.
33. 2+ channels in rat islet beta-cells. Br J Pharmacol 1999;126:1205-13.
34. von Eckardstein A, Sibler RA. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011;22:26-32.
35. Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol 2011;26:342-7.
36. Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.
37. Baker WL, Talati R, White CM et al. Differing effect of statins on Insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87:98-107.
38. Sukhija R, Prayaga S, Marashdeh M et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009;57:495-9.
39. Huptas S, Geiss HC, Otto C et al. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol 2006;98:66-9.
40. Park JS, Kim YJ, Choi JY et al. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med 2010;25:27-35.
41. Koh KK, Quon MJ, Han SH et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010;55:1209-16.
42. Waters DD, Ho JE, DeMicco DA et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57:1535-45.
43. Waters DD, Ho JE, Boekholdt SM et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013;61:148-52.
44. Gannagé-Yared MH, Azar RR, Amm-Azar M et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 2005,54:947-51.
45. Sugiyama S, Fukushima H, Kugiyama K et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007;194:e43-e51.
46. Kjekshus J, Apetrei E, Barrios V et al. for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.
47. Thongtang N, Ai M, Otokozawa S et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol 2011;107:387-92.
48. ter Avest E, Abbink EJ, de Graaf J et al. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest 2005;35:558-64.
49. Ridker PM, Pradhan A, MacFadyen JG et al. Cardiovascular benefits and diabetic risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-71.
50. Koh KK, Ahn JY, Quon MJ et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008;31:776-82.
51. Szendroedi J, Brehm A, Anderwald C et al. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes Care 2009;32:209-14.
52. Kawai Y, Sato-Ishida R, Motoyama A et al. Place of pravastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. Drug Des Devel Ther 2011;5:283-97.
53. Yokote K, Saito Y. for CHIBA Study investigators. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the Collaborative Study on Hypercholesterolemia Drug Intervention and their Benefits for Atherosclerosis Prevention (CHIBA Study). J Atheroscler Thromb 2009;16:297-8.
54. Yamakawa T, Takano T, Tanaka S et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008;15:269-75.
55. Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. J Am Coll Cardiol Intv 2008;1:211-7.
56. Brookhart MA, Stürmer T, Glynn RJ et al. Confounding control in healthcare database research: challenges and potential approaches. Med Care 2010;48(SUPPL. 1):S114-S120.
57. Thangaratinam S, Redman CW. The Delphi technique. The Obstetrician & Gynaecologist (TOG) 2005;7:120-5.
58. Colhoun HM, Betteridge DJ, Durrington PN et al. on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004;364:685-96.
59. Knopp RH, d'Emden M, Smilde JG et al. on behalf of the ASPEN Study Group. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes. Diabetes Care 2006;29:1478-85.
60. Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006;13:123-9.
61. Blaha MJ, Nasir K, Blumenthal RS Statin therapy for healthy men identified as "increased risk." JAMA 2012;308:1489-90.
62. Byrne CD, Wild SH. Increased risk of glucose intolerance and type 2 diabetes with statins. BMJ 2011;343:d5004.
63. Hilmer S, Gnjidic D. Statins in older adults. Aust Prescr 2013;36:79-82.
64. Spensce D. Bad medicine: statins. BMJ 2013;346:f3566.
65. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
66. Savarese G, Gotto AM, Paolillo S et al. Benefits of statins in elderly subjects without established cardiovascular disease. A meta-analysis. J Am Coll Cardiol 2013;62:2090-9.
67. Taylor F, Huffman MD, Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816.
68. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. February 28, 2012. Available at http://www.fda.gov/Drugs/DrugSafety/ucm293101. Accessed September 30, 2013.
69. New statins labeling update: risk of increased blood sugar levels and diabetes. http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/16949a-eng.php. Accessed September 30, 2013.